Cingulate Inc. (CING) awards 80,000 stock options to chief medical officer

Rhea-AI Filing Summary

Cingulate Inc. granted stock options to EVP and Chief Medical Officer Matthew Brams on July 16, 2026. He received options to purchase 53,600 and 26,400 shares of common stock at an exercise price of $4.43 per share, expiring on July 16, 2036.

Both option grants vest 25% on March 31, 2027, with the remainder vesting in substantially equal monthly installments over 36 months. The 26,400-share option becomes exercisable only if the issuer’s NDA for CTx-1301 is approved by the FDA during 2027, otherwise the entire option terminates.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Brams Matthew

Role EVP and Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to Buy) F1	53,600	$0.00	$0.00
Grant/Award	Stock Option (right to Buy) F1, F2, F3	26,400	$0.00	$0.00

Holdings After Transaction: Stock Option (right to Buy) — 80,000 shares (Direct)

Footnotes (3)

1. F1. The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date.
2. F2. Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027.
3. F3. If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate.

Key Figures

Time-based option grant: 53600 shares Performance-contingent option grant: 26400 shares Exercise price: $4.4300 per share +3 more

6 metrics

Time-based option grant 53600 shares Stock options to purchase 53,600 shares of common stock granted July 16, 2026

Performance-contingent option grant 26400 shares Stock options to purchase 26,400 shares of common stock granted July 16, 2026

Exercise price $4.4300 per share Exercise price for both option grants to purchase Cingulate common stock

Regulatory approval contingency year 2027 26,400-share option exercisable only if CTx-1301 NDA is approved by FDA during 2027

Option expiration date 2036-07-16 Expiration date for both stock option grants awarded to Matthew Brams

Initial vesting date March 31, 2027 25% of each option grant vests on March 31, 2027, with remaining monthly over 36 months

Key Terms

stock option, vests, NDA, CTx-1301, +1 more

5 terms

stock option financial

"The option vests as follows: 25% on March 31, 2027 and the remaining shares"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vests financial

"The option vests as follows: 25% on March 31, 2027 and the remaining"

NDA regulatory

"Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is"

An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.

CTx-1301 medical

"Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is"

exercisable financial

"Vested option only becomes exercisable if the Issuer's NDA for CTx-1301"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/20/2026 - 07:32 PM Accepted by SEC EDGAR 07/20/2026 - 07:32 PM Learn about SEC filing dates

FAQ

What insider transaction did Cingulate Inc. (CING) report for Matthew Brams?

Cingulate reported that EVP and Chief Medical Officer Matthew Brams received two stock option grants on July 16, 2026. The grants cover 53,600 and 26,400 shares of common stock at an exercise price of $4.43 per share, expiring July 16, 2036.

What are the vesting terms of the new stock options granted by Cingulate (CING)?

Both option grants to Matthew Brams vest 25% on March 31, 2027. The remaining shares vest in substantially equal monthly installments over the following 36-month period, creating a four-year vesting schedule tied to continued service.

What is the exercise price of the Cingulate (CING) options granted to Matthew Brams?

Each option grant to Matthew Brams carries an exercise price of $4.43 per share. These options give him the right to buy Cingulate common stock at that fixed price until their July 16, 2036 expiration, subject to vesting and other conditions.

What regulatory milestone affects the 26,400-share option grant at Cingulate (CING)?

The 26,400-share option only becomes exercisable if Cingulate’s NDA for CTx-1301 is approved by the FDA during 2027. If that NDA is not approved during 2027, the option, including any portion that has vested, will terminate completely.

Are the new Cingulate (CING) stock option grants to Matthew Brams immediately exercisable?

No, the options are not immediately exercisable. They begin vesting with 25% on March 31, 2027 and then monthly over 36 months. In addition, the 26,400-share grant requires FDA approval of the CTx-1301 NDA in 2027 to become exercisable.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brams Matthew

(Last) (First) (Middle)

1901 W. 47TH PLACE

(Street)

KANSAS CITY KANSAS 66205

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cingulate Inc. [ CING ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to Buy)	$4.43	07/16/2026		A		53,600		(1)	07/16/2036	Common Stock	53,600	$0	53,600	D
Stock Option (right to Buy)	$4.43	07/16/2026		A		26,400		(1)(2)	07/16/2036(3)	Common Stock	26,400	$0	26,400	D

Explanation of Responses:

1. The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date.

2. Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027.

3. If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate.

	/s/ Shane J. Schaffer, Attorney-in-Fact	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)